2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Glycolate Oxidase
  5. Glycolate Oxidase Inhibitor

Glycolate Oxidase Inhibitor

Glycolate Oxidase Inhibitors (2):

Cat. No. Product Name Effect Purity
  • HY-132588
    Lumasiran
    		Inhibitor
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
  • HY-132613
    Lumasiran sodium
    		Inhibitor 99.21%
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .